Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$27.32 USD

27.32
1,903,992

-0.31 (-1.12%)

Updated Jul 31, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo.

Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered

by Zacks Equity Research

Bristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.

Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Alkermes (ALKS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 14.58% and 7.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.

Philips (PHG) Q2 Earnings Beat Estimates, Revenue Rise Y/Y

by Zacks Equity Research

Philips' (PHG) second-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

by Zacks Equity Research

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.

Vir Biotechnology (VIR) Down on Influenza Study Failure

by Zacks Equity Research

Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.

Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Alkermes' (ALKS) key drugs like Vivitrol, Aristada and Lybalvi are likely to have driven second-quarter sales.

J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps

by Zacks Equity Research

J&J (JNJ) beats estimates for second-quarter earnings and sales. It raises full-year sales and earnings guidance.

Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why

by Zacks Equity Research

Recursion's (RXRX) shares rallied almost 191% over the past three months, owing to artificial intelligence-driven acquisitions and strategic collaborations to advance drug development.

Apellis (APLS) Plunges on Safety Issues With Eye Treatment

by Zacks Equity Research

Apellis (APLS) suffers a setback on reports of six events of retinal vasculitis (or inflammation) following treatment with Syfovre (pegcetacoplan injection).

Alkermes (ALKS) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises

by Zacks Equity Research

Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.

Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised

by Zacks Equity Research

Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.

BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study

by Zacks Equity Research

BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.

Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data

by Zacks Equity Research

Corcept's (CORT) early-stage candidate miricorilant, evaluated to treat patients with presumed non-alcoholic steatohepatitis, shows encouraging data.

Frequency (FREQ) Up 77% on Merger Deal With Korro Bio

by Zacks Equity Research

Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.

Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion

by Zacks Equity Research

Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.

Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio

by Zacks Equity Research

For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.

Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill

by Zacks Equity Research

Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.

First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback

by Zacks Equity Research

Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.